A Brief Review on Formulation and Evalution of Corticosteroid Prednisolone Gummies

Prednisolone is a widely used corticosteroid for treating inflammatory and autoimmune conditions. However, its conventional dosage forms, such as tablets and syrups, often present challenges for pediatric patients due to bitter taste and difficulty in swallowing Prednisolone is a corticosteroid medication commonly used to treat various conditions such as inflammation, autoimmune diseases, and allergic reactions. Traditionally available in tablet and liquid form, prednisolone can be challenging to administer, especially for children or individuals with difficulty swallowing pills. To address this, the development of prednisolone gummies has emerged as a more patient-friendly alternative. Prednisolone gummies combine the therapeutic effects of prednisolone with the convenience of a chewable form. These gummies are designed to provide accurate dosing in an easy-to-consume format, improving patient adherence to treatment regimens. The formulation ensures that the active ingredient, prednisolone, is effectively delivered while maintaining stability and bioavailability. Global policy changes have increased access to products containing cannabidiol (CBD), a primary constituent of hemp and cannabis. The CBD product industry has experienced tremendous growth, in part, because CBD is widely touted as an effective therapeutic for myriad health conditions. However, only CBD product (Epidiolex®) has been approved by the U.S. Food and Drug Administration (FDA) to date. There is substantial interest among consumers and the medical and scientific communities regarding the therapeutic potential of CBD, including for novel indications that are not recognized by the FDA. The purpose of this review was to synthesize available evidence from clinical research regarding the efficacy of CBD oil as a therapeutic agent.